<DOC>
	<DOCNO>NCT00486382</DOCNO>
	<brief_summary>The purpose study determine vaccine ( call Leish-111f + MPL-SE ) safe whether produce protective response visceral leishmaniasis inject healthy subject .</brief_summary>
	<brief_title>Open-Label Safety Study Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE Healthy Adults India</brief_title>
	<detailed_description>The purpose study determine safety , tolerability , immunogenicity investigational vaccine develop immunotherapy visceral leishmaniasis ( VL ) post kala-azar dermal leishmaniasis ( PKDL ) . The vaccine , identify Leish-111f + MPL-SE , consist recombinant three-antigen Leishmania polyprotein ( Leish-111f ) together adjuvant MPL-SE . The primary objective evaluate safety tolerability Leish-111f + MPL-SE vaccine give three subcutaneous injection every 28 day three dose level Leish-111f protein ( 5 μg , 10 μg , 20 μg ) together MPL-SE adjuvant ( 25 μg ) healthy adult . The secondary objective ass immunogenicity vaccine evaluate T-cell antibody response Leish-111f protein vaccine .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males female ≥ 18 year &lt; 55 year age . Must good general health confirm medical history physical exam . DAT titer must &lt; 1:400 rK39 serology negative ( inclusion DATnegative group ) DAT titer ≥1:1600 ( inclusion DATpositive group ) . The following laboratory blood test must value within normal range screen ( Appendix 4 ) : sodium , potassium , urea , ALT , AST , total bilirubin , creatinine , alkaline phosphatase , glucose , hemoglobin , total WBC count platelet count . The following serology test must negative screening : HIV 1/2 , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody . All subject receive HIV relate counsel prior test . Subjects positive HIV test result receive counsel University refer national AIDS control program treatment appropriate . Subjects must give write informed consent , willing able attend require visit , permanent address , reachable study site personnel . Female subject childbearing potential must negative urine pregnancy test screening , negative urine pregnancy test within 24 hour study injection , must breastfeed , require use adequate contraception Day 84 study . These precaution necessary due unknown effect Leish111f + MPLSE might fetus newborn infant . Previous exposure Leishmania vaccine experimental product contain MPLSE . Participation another experimental protocol receipt investigational product within 30 day prior first administration study injection . Known use injected oral corticosteroid within 6 week prior first administration study injection . History autoimmune disease cause immunosuppressive state . History evidence acute chronic illness , opinion Principal Investigator , may interfere evaluation safety immunogenicity vaccine . ( Potential subject present concomitant illness refer clinical care . ) History use medication , opinion Principal Investigator , may interfere evaluation safety immunogenicity vaccine . History significant psychiatric illness . Known current drug alcohol abuser . Subjects history previous anaphylaxis , severe allergic reaction vaccine unknown allergen , allergic reaction egg . History chronic headache migraine . Subjects unlikely cooperate requirement study protocol . Subjects permanent resident plan move another town/city .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>visceral leishmaniasis</keyword>
	<keyword>vaccine</keyword>
</DOC>